BRCA2 and breast carcinoma: Which moderate-risk breast CSGs are tested can vary between centres but a recent work by Dorling et al. recommend a hereditary breast cancer screening panel of ATM, BARD1, BRCA1, BRCA2, CHEK2, PALB2, RAD51C, RAD51D and TP53 would contain the most clinically useful CSGs [26].